Published in Gene Therapy Weekly, June 2nd, 1997
In previous research, Masahiro Toda and colleagues from the Georgetown University Medical Center, Washington, DC, demonstrated that G207 had therapeutic potential for the treatment of human malignant brain tumors. G207 is an HSV-1 virus manipulated by the researchers and characterized by deletions in both gamma 34.5 loci and a lacZ insertion. These changes result in the inactivation of the ICP6 gene and cause it to replicate selectively in dividing cells, while sparing non-dividing cells.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.